Kangtai Biological's COVID-19 vaccine gets emergency use approval in China

Baku, May 16, AZERTAC

China's drug authority has granted emergency use approval to a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products, the company said on Friday, according to CGTN.

In a statement, Kangtai said it is currently conducting Phase III trials for the inactivated vaccine.

It is the sixth approved vaccine after two from Sinopharm, one from Sinovac, one from CanSino and one from the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS).

Kangtai has also obtained the exclusive right to develop and manufacture the vaccine developed by AstraZeneca and Oxford University on the Chinese mainland.

© Content from this site must be hyperlinked when used.
Report a mistake by marking it and pressing ctrl + enter


Fields with * are required.

Please enter the letters as they are shown in the image above.
Letters are not case-sensitive.